Nuclear PI-PLCβ1 and myelodysplastic syndromes: Genetics and epigenetics

Current Pharmaceutical Design

Volumn 18, Issue 13, 2012, Pages 1751-1754

  Follo, Matilde Y ^a   Mongiorgi, Sara ^a   Finelli, Carlo ^a   Piazzi, Manuela ^a   Faenza, Irene ^a   Ramazzotti, Giulia ^a   Santi, Patrizia ^a   McCubrey, James A ^b   Martelli, Alberto M ^a   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Epigenetics; Myelodysplastic syndromes; Nucleus; PI PLC 1; Signal transduction

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLIN D3; DNA METHYLTRANSFERASE; GROWTH FACTOR; INOSITOL 1,4,5 TRISPHOSPHATE; LENALIDOMIDE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHOLIPASE C BETA1; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HISTONE MODIFICATION; HUMAN; INTERSTITIAL CHROMOSOME DELETION; INTRACELLULAR SIGNALING; LEUKEMOGENESIS; LIPID METABOLISM; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL NUCLEUS; EPIGENESIS, GENETIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PHOSPHOLIPASE C BETA; SIGNAL TRANSDUCTION;

EID: 84860128450     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799859710     Document Type: Article

References (50)

1. Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep 2011; 6:145-153.
2. Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7:118-129.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-199.
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088.
6. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503-3510.
7. Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep 2011; 6:13-21.
8. Morgan MA, Reuter CW. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 2006; 85:139-163.
9. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008; 112:1089-1095.
10. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011; 29:516-523.
11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
12. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11:3604-3608.
13. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45:23-30.
14. Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15:6732-6739.
15. Park S, Chapuis N, Bardet V, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008.
16. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26:5943-5949.
17. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638-1645.
18. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007; 109:4158-4163.
19. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-1465.
20. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009; 113:3947-3952.
21. Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother 2008; 9:1667-1678.
22. Cutler C. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2010; 2010:325-329.
23. Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31:536-546.
24. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138:3-11.
25. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005; 2 Suppl 1:S12-S23.
26. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22:965-970.
27. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123:8-13.
28. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100:2957-2964.
29. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007; 21:1937-1944.
30. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106:112-119.
31. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15:5002-5007.
32. Martelli AM, Gilmour RS, Bertagnolo V, et al. Nuclear localization and signalling activity of phosphoinositidase C p in Swiss 3T3 cells. Nature 1992; 358:242-245.
33. Faenza I, Bregoli L, Ramazzotti G, et al. Nuclear phospholipase C p1 and cellular differentiation. Front Biosci 2008; 13:2452-2463.
34. Martelli AM, Follo MY, Evangelisti C, et al. Nuclear inositol lipid metabolism: more than just second messenger generation? J Cell Biochem 2005; 96:285-292.
35. Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 2010; 1803:991-1002.
36. Follo MY, Mongiorgi S, Finelli C, et al. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem 2010; 109:1065-1071.
37. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23:25-42.
38. Nyakern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006; 20:230-238.
39. Follo MY, Mongiorgi S, Bosi C, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007; 67:4287-4294.
40. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35:1739-1746.
41. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003; 33:153-160.
42. Suh PG, Park JI, Manzoli L, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 2008; 41:415-434.
43. Cocco L, Faenza I, Follo MY, et al. Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. Adv Enzyme Regul 2009; 49:2-10.
44. Cocco L, Follo MY, Faenza I, et al. Inositide signaling in the nucleus: From physiology to pathology. Adv Enzyme Regul 2009.
45. Ramazzotti G, Faenza I, Fiume R et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol 2011; 226:14-20.
46. Peruzzi D, Calabrese G, Faenza I, et al. Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C p(1). Biochim Biophys Acta 2000; 1484:175-182.
47. Follo MY, Finelli C, Clissa C, et al. Phosphoinositide- phospholipase C β1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol 2009; 27:782-790.
48. Follo MY, Bosi C, Finelli C, et al. Real-time PCR as a tool for quantitative analysis of PI-PLCβ1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006; 18:267-271.
49. Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C β1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009; 106:16811-16816.
50. Follo MY, Finelli C, Mongiorgi S, et al. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011; 25:271-280.